Folate receptors are up-regulated on a variety of human cancers, including cancers of the
breast, ovaries, endometrium, lungs, kidneys, colon, brain, and myeloid cells of …

Conventional cancer treatment modalities have several limitations including lack of sufficient
efficacy, serious untoward toxicity, as well as innate and acquired drug resistance. In …

The membrane-bound folate receptor (FR) is overexpressed on a wide range of human
cancers, such as those originating in ovary, lung, breast, endometrium, kidney and brain …

The folate receptor (FR) is overexpressed on a variety of tumor types, whereas its
distribution in normal tissues and organs is highly limited. Exploration of the utility of the FR …

The folate receptor-α (FR-α) is overexpressed in many epithelial cancers, including ovary,
uterus, kidneys, breast, lung, colon and prostate carcinomas, but shows limited expression …

Over-expression of folate receptor alpha on cancer cells has been frequently exploited for
delivery of folate-targeted imaging and therapeutic agents to tumors. Because limited …

The cell-membrane folate receptor is a potential molecular target for tumor-selective drug
delivery, including delivery of radiolabeled folate–chelate conjugates for diagnostic imaging …

Folate receptor α (FRα) came into focus as an anticancer target many decades after the
successful development of drugs targeting intracellular folate metabolism, such as …

Folate receptor (FR) can be used as a therapeutic target because of its expression on
different epithelial cancers, such as ovarian, non–small cell lung, endometrial, and breast …

The vitamin folic acid (FA) enters cells either through a carrier protein, termed the reduced
folate carrier, or via receptor-mediated endocytosis facilitated by the folate receptor (FR) …